Related Experiment Video
Updated: Jan 23, 2026

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
Published on: November 10, 2023
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia
Nicolas Chapuis1,2,3,4,5, Laury Poulain1,2,3,4, Rudy Birsen1,2,3,4
1INSERM U1016, Institut Cochin, Paris, France.
Abstract:
Metabolic reprogramming is a common cancer cell phenotype as it sustains growth and proliferation. Targeting metabolic activities offers a wide range of therapeutic possibilities which are applicable to acute myeloid leukemia (AML). Indeed, in addition to the IDH1/2-mutated AML model which established the proof-of-concept for specifically targeting metabolic adaptations in AML, several recent reports have expanded the scope of such strategies in these diseases. This review highlights recent findings on metabolic deregulation in AML and summarizes their implications in leukemogenesis.
Insights
Metabolic reprogramming fuels cancer cell growth. Targeting these metabolic changes shows promise for treating acute myeloid leukemia (AML), offering new therapeutic avenues.
Area of Science:
- Oncology
- Metabolic pathways
- Cancer cell biology
Background:
- Metabolic reprogramming is a hallmark of cancer, supporting uncontrolled cell growth and proliferation.
- Acute myeloid leukemia (AML) cells exhibit significant metabolic alterations.
- Targeting cancer metabolism presents a promising therapeutic strategy.
Purpose of the Study:
- To review recent findings on metabolic deregulation in AML.
- To summarize the implications of these metabolic changes in leukemogenesis.
- To highlight the therapeutic potential of targeting metabolic pathways in AML.
Main Methods:
- Literature review of recent studies on AML metabolism.
- Analysis of metabolic adaptations in various AML subtypes.
- Synthesis of data on therapeutic strategies targeting metabolic pathways.
Main Results:
- Recent reports expand the scope of metabolic targeting in AML beyond IDH1/2 mutations.
- Specific metabolic pathways are crucial for AML cell survival and proliferation.
- Targeting metabolic vulnerabilities can inhibit AML progression.
Conclusions:
- Metabolic reprogramming is a critical driver of leukemogenesis in AML.
- Targeting metabolic pathways offers a viable and expanding therapeutic approach for AML.
- Further research into AML metabolic dependencies will uncover novel treatment strategies.
Related Concept Videos
What is Metabolism?
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...
Therapeutic Index
Other Glycolytic Pathways
Respiration Pathways
Auditory Pathway
When viewed cross-sectionally, the cochlea reveals the scala vestibuli and scala tympani flanking...

